Cargando…
Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms
BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that converts tryptophan to kynurenine. IDO1 expression is found not only in tumor cells but also in immune cells and is associated with tumor proliferation and immune responses. IDO1 inhibitors and radiation may cooperatively suppress tu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847047/ https://www.ncbi.nlm.nih.gov/pubmed/36653774 http://dx.doi.org/10.1186/s12885-023-10539-5 |
_version_ | 1784871347095076864 |
---|---|
author | Nozawa, Hiroaki Taira, Tetsuro Sonoda, Hirofumi Sasaki, Kazuhito Murono, Koji Emoto, Shigenobu Yokoyama, Yuichiro Nagai, Yuzo Abe, Shinya Ishihara, Soichiro |
author_facet | Nozawa, Hiroaki Taira, Tetsuro Sonoda, Hirofumi Sasaki, Kazuhito Murono, Koji Emoto, Shigenobu Yokoyama, Yuichiro Nagai, Yuzo Abe, Shinya Ishihara, Soichiro |
author_sort | Nozawa, Hiroaki |
collection | PubMed |
description | BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that converts tryptophan to kynurenine. IDO1 expression is found not only in tumor cells but also in immune cells and is associated with tumor proliferation and immune responses. IDO1 inhibitors and radiation may cooperatively suppress tumor proliferation through the alterations in the Wnt/β-catenin pathway, cell cycle, and immune response. We investigated the antitumor effects of combination therapy of an IDO1 inhibitor, 1-methyl tryptophan (1-MT), and radiation on colorectal cancer. METHODS: In vitro experiments were conducted using human and murine colon cancer cell lines (HCT116, HT-29, and Colon26). Cell growth inhibition was assessed using a MTS assay and Clonogenic assay. Cells were cultured for 48 h with or without 500 µM 1-MT after exposure to radiation (4 Gy). Cell cycle effects and modulation of Wnt/β-catenin pathway were evaluated using western blot analysis, flow cytometry, RT-PCR. Subcutaneous Colon26 tumors in BALB/c mice were treated by oral 1-MT (6 mg/mL) for 2 weeks and/or local radiation (10 Gy/10 fr). Bromodeoxyuridine (BrdU) incorporation in tumor cells and expression of differentiation markers of immune cells were evaluated using immunohistochemistry. RESULTS: 1-MT and a small interfering RNA against IDO1 suppressed proliferation of all cell lines, which was rescued by kynurenine. Clonogenic assay showed that administration of 1-MT improved radiosensitivity by suppressing the Wnt/β-catenin pathway activated by radiation and enhancing cell cycle arrest induced by radiation. Combination therapy showed a further reduction in tumor burden compared with monotherapies or untreated control, inducing the highest numbers of intratumoral CD3 + and CD8 + T cells and the lowest numbers of Foxp3 + and BrdU-positive tumor cells. CONCLUSIONS: The combination of 1-MT and radiation suppressed colon cancer cells in vitro and in vivo via multiple mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10539-5. |
format | Online Article Text |
id | pubmed-9847047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98470472023-01-19 Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms Nozawa, Hiroaki Taira, Tetsuro Sonoda, Hirofumi Sasaki, Kazuhito Murono, Koji Emoto, Shigenobu Yokoyama, Yuichiro Nagai, Yuzo Abe, Shinya Ishihara, Soichiro BMC Cancer Research BACKGROUND: Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that converts tryptophan to kynurenine. IDO1 expression is found not only in tumor cells but also in immune cells and is associated with tumor proliferation and immune responses. IDO1 inhibitors and radiation may cooperatively suppress tumor proliferation through the alterations in the Wnt/β-catenin pathway, cell cycle, and immune response. We investigated the antitumor effects of combination therapy of an IDO1 inhibitor, 1-methyl tryptophan (1-MT), and radiation on colorectal cancer. METHODS: In vitro experiments were conducted using human and murine colon cancer cell lines (HCT116, HT-29, and Colon26). Cell growth inhibition was assessed using a MTS assay and Clonogenic assay. Cells were cultured for 48 h with or without 500 µM 1-MT after exposure to radiation (4 Gy). Cell cycle effects and modulation of Wnt/β-catenin pathway were evaluated using western blot analysis, flow cytometry, RT-PCR. Subcutaneous Colon26 tumors in BALB/c mice were treated by oral 1-MT (6 mg/mL) for 2 weeks and/or local radiation (10 Gy/10 fr). Bromodeoxyuridine (BrdU) incorporation in tumor cells and expression of differentiation markers of immune cells were evaluated using immunohistochemistry. RESULTS: 1-MT and a small interfering RNA against IDO1 suppressed proliferation of all cell lines, which was rescued by kynurenine. Clonogenic assay showed that administration of 1-MT improved radiosensitivity by suppressing the Wnt/β-catenin pathway activated by radiation and enhancing cell cycle arrest induced by radiation. Combination therapy showed a further reduction in tumor burden compared with monotherapies or untreated control, inducing the highest numbers of intratumoral CD3 + and CD8 + T cells and the lowest numbers of Foxp3 + and BrdU-positive tumor cells. CONCLUSIONS: The combination of 1-MT and radiation suppressed colon cancer cells in vitro and in vivo via multiple mechanisms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-10539-5. BioMed Central 2023-01-18 /pmc/articles/PMC9847047/ /pubmed/36653774 http://dx.doi.org/10.1186/s12885-023-10539-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nozawa, Hiroaki Taira, Tetsuro Sonoda, Hirofumi Sasaki, Kazuhito Murono, Koji Emoto, Shigenobu Yokoyama, Yuichiro Nagai, Yuzo Abe, Shinya Ishihara, Soichiro Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title | Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title_full | Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title_fullStr | Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title_full_unstemmed | Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title_short | Enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
title_sort | enhancement of radiation therapy by indoleamine 2,3 dioxygenase 1 inhibition through multimodal mechanisms |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847047/ https://www.ncbi.nlm.nih.gov/pubmed/36653774 http://dx.doi.org/10.1186/s12885-023-10539-5 |
work_keys_str_mv | AT nozawahiroaki enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT tairatetsuro enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT sonodahirofumi enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT sasakikazuhito enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT muronokoji enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT emotoshigenobu enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT yokoyamayuichiro enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT nagaiyuzo enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT abeshinya enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms AT ishiharasoichiro enhancementofradiationtherapybyindoleamine23dioxygenase1inhibitionthroughmultimodalmechanisms |